Figures & data
Table 1 Rescue Primers Used When Samples Failed to Amplify
Table 2 Baseline Demographics and Clinical Characteristics for Study Participants
Figure 1 Genotyping success of in-house RNA-based HIV genotyping assay, overall and stratified by VL group.
![Figure 1 Genotyping success of in-house RNA-based HIV genotyping assay, overall and stratified by VL group.](/cms/asset/3ee6905e-cc9f-42a9-917d-543e3f3354a2/didr_a_12154284_f0001_c.jpg)
Figure 2 Association of genotyping outcomes with viral load measurement.
![Figure 2 Association of genotyping outcomes with viral load measurement.](/cms/asset/8f05089d-0cc6-44bb-bd0c-39424902ac94/didr_a_12154284_f0002_c.jpg)
Figure 3 Maximum likelihood phylogenetic tree constructed using 1000 bootstrap values showing the uniqueness of the sequences and that there is no clustering of sequences by their VL group. The light-blue dot represents standard HIV reference strain.
![Figure 3 Maximum likelihood phylogenetic tree constructed using 1000 bootstrap values showing the uniqueness of the sequences and that there is no clustering of sequences by their VL group. The light-blue dot represents standard HIV reference strain.](/cms/asset/7a197d28-26a5-4a58-b6c4-71d686783a56/didr_a_12154284_f0003_c.jpg)
Table 3 Prevalence of HIV DRM, Overall and by VL Groups
Figure 4 HIV DRM classified by NRTI and NNRTI resistance classes (N=76) using an in-house RNA-based HIV genotyping assay with detectable plasma HIV-1 RNA > 400 copies/mL.
![Figure 4 HIV DRM classified by NRTI and NNRTI resistance classes (N=76) using an in-house RNA-based HIV genotyping assay with detectable plasma HIV-1 RNA > 400 copies/mL.](/cms/asset/7355aa16-64d9-41da-b6c9-30a002179fb5/didr_a_12154284_f0004_c.jpg)